Department of Medicine

Research

Breakthrough research leads to improved patient care

Department of Medicine researchers have made important contributions to the development of novel therapies that are improving patient outcomes.

Clinical Trials by Condition

APS (Antiphospholipid Syndrome)

IRB#
Clinical Trial
Principal Investigator
13221
An Open Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome
Doruk Erkan, MD, MPH
11179
A Prospective, Randomized-Controlled Trial Comparing Hydroxychloroquine in the Primary Thrombosis Prophylaxis of Persistently Antiphospholipid Antibody (aPL) Positive but Thrombosis-free Patients without Systemic Autoimmune Diseases.
Doruk Erkan, M.D.
11180
APS ACTION (Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking) International Clinical Database and Repository.
Doruk Erkan, M.D
12186
Comparison of Gut Commensal Bacteria between Persistently Anti-beta2 Glycoprotein-1 Positive Patients and Antiphospholipid Antibody Negative Patients
Doruk Erkan, MD
28005
Effects of Fluvastatin on Proinflammatory and Prothrombotic markers in Antiphospholipid Syndrome
Doruk Erkan, MD
28023
Cognitive Dysfunction, Diffusion Tensor Imaging and Functional Magnetic Resonance Imaging (MRI) in Antiphospholipid Antibody (aPL)-negative Systemic Lupus Erythematosus (SLE) versus aPL-positive non-SLE Patients
Doruk Erkan, MD
10130
Effect of Hydroxychloroquine on the Annexin A5 Resistance Assay in Antiphospholipid Antibody-Positive Patients with and without Systemic Lupus Erythematosus
Doruk Erkan, MD
27022
RITAPS: A Pilot Study Of Rituximab For The Anticoagulation-Resistant Manifestations Of Antiphospholipid Syndrome (APS)
Doruk Erkan, MD
22122
PROMISSE: Predictors of Pregnancy Outcome: Biomarkers in Anti-Phospholipid Antibody Syndrome (APS) and Systemic Lupus Erythematosus (SLE)
Jane E. Salmon, MD
95004
Autoimmune Disease Registry and Repository
Jane E. Salmon, MD

Arthritis

IRB#
Clinical Trial
Principal Investigator
11095
Studies of Immune Deregulation in Patients with Rheumatoid Arthritis, Polymyalgia Rheumatica and Vasculitis
Alessandra B. Pernis, MD
25097
Arthritis Intervention Programs for People with Arthritis and Related Disease
Laura Robbins, DSW
12046
Retrospective Review of Education Programs for People with Musculoskeletal Disorders
Laura Robbins, DSW
11096
Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry38880
Thomas J.A. Lehman, MD
23034
Open Label Trial for Treating Carpometacarpal Osteoarthritis: PILOT STUDY - Sub-study on Normal Controls
Lisa A. Mandl, MD, MPH
23108
Evaluation of Intra-articular Injuries as Predictors of Function and Arthritis
Robert G. Marx, MD
26043
A Study of Hyaluronan (Synvisc) for the Treatment of Osteoarthritis in the Thumb: Randomized Control Trial
Lisa A. Mandl, MD, MPH
26035
Arthroscopic Partial Meniscectomy in Osteoarthritis: A Randomized Control Trial
Lisa A. Mandl, MD, MPH
25022
Quantitative Assessment of the Synovial Vascularity in Early Inflammatory Arthritis
Lisa A. Mandl, MD, MPH
24067
Database of the Gosden Robinson Early Arthritis Center (EAC): Analysis of Types of Patients Recruited to an Urban EAC
Lisa C. Vasanth, MD
22007
Hyalgan Treatment of Osteoarthritis in Post-Operative Knee Arthroplasty Patients
Geoffrey Westrich, MD

Lupus

IRB#
Clinical Trial
Principal Investigator
11113
A Phase 2B, Dose Ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with SLE
Kyriakos A. Kirou, MD, DSc, FACP
10117
A Phase 1 Double Blind, Randomized, Single Ascending Dose Study of the Safety and Tolerability of MEDI 570 in SLE
Kyriakos A. Kirou, MD
10130
Effect of Hydroxychloroquine on the Annexin A5 Resistance Assay in Antiphospholipid Antibody-Positive Patients with and without Systemic Lupus Erythematosus
Doruk Erkan, MD
11141
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMINATE-2)
Doruk Erkan, M.D.
13219
A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race with Systemic Lupus Erythematosus (SLE)
Kyriakos A. Kirou, MD, DSc, FACP
14008
Focus Groups to Gather Patient Preferences about the HSS Smartphone Application for Systemic Lupus Erythematosus
Alana B. Levine, MD
22122
PROMISSE: Predictors of Pregnancy Outcome: Biomarkers in Anti-Phospholipid Antibody Syndrome (APS) and Systemic Lupus Erythematosus (SLE)
Jane E. Salmon, MD
93029
Fc Receptor Function in Normals and Systemic Lupus Erythematosus (SLE)
Jane E. Salmon, MD
95004
Autoimmune Disease Registry and Repository
Jane E. Salmon, MD

Please visit the Mary Kirkland Center for Lupus Research and the Lupus Clinical Trials Consortium for more information on lupus research.

Scleroderma

IRB#
Clinical Trial
Principal Investigator
13224
The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)
Robert F. Spiera, MD
13004
ASCI: A Randomized, Double-blind, Placebo-controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Scllerosis-Associated Pulonary Arterial Hypertension (SSc-PAH)
Robert F. Spiera, MD
12086
Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Parallel group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients with Ischemic Digital Ulcers Associated with Systemic Sclerosis
Robert F. Spiera, MD
12136
Phase II/III, Multicenter, Randomized, Double-blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab vs. Placebo in Patients with Systemic Sclerosis
Robert F. Spiera, MD
12006
Bellumimab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Robert F. Spiera, MD
10115
Natural History and Outcome of Scleroderma Patients at High Risk or with Early Pulmonary Hypertension
Jessica Gordon, MD
10041
Nilotinib in the Treatment of Systemic Sclerosis
Robert F. Spiera, MD
10068
DISTOL 1: Digital Ischemic Lesions in Scleroderma Treated with Oral Treprostinil Diethanolamine: a Randomized, Double-blind, Placebo-controlled, Multicenter Study
Robert F. Spiera, MD
26069
Scleroderma Registry
Robert Spiera, MD
27049
Gleevec in the Treatment of Systemic Sclerosis
Robert F. Spiera, MD
^ Back to Top
Request an Appointment